Literature DB >> 22000171

Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma?

Jeffrey A Glant1, Joshua A Waters, Michael G House, Nicholas J Zyromski, Atilla Nakeeb, Henry A Pitt, Keith D Lillemoe, C Max Schmidt.   

Abstract

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a propensity for early metastasis that is often encountered unexpectedly at operation. Our objective was to examine the effect of the time interval between preoperative imaging and attempted resection and the venue in which imaging was performed on the frequency of unanticipated metastasis (UM) encountered at operation. We hypothesize that imaging obtained locally at our hospital and within 4 weeks of operation will result in a lesser frequency of UM encountered at operation.
METHODS: Between January 2004 and December 2009, records of patients undergoing planned pancreatic resection for PDAC at a high volume pancreatic surgery center were compiled. Exclusion criteria included neoadjuvant therapy, prior pancreatic resection, or evidence of metastasis on imaging. Review and analysis of clinical, radiographic, operative, and pathologic data were undertaken. Frequency of UM and outcome of resection was compared with the interval between most recent cross-sectional imaging (dual-phase contrast-enhanced CT or MRI) and operation defined as imaging-to-operation interval (IOI).
RESULTS: Four-hundred eighty-seven patients met eligibility requirements for the study: 431 (88%) proximal and 56 (12%) distal PDAC. 202 (41%) patients had their most recent imaging performed at an outside institution, and no difference in the rates of UM was observed whether imaging was conducted at our institution or at an outside institution (P > .05). Of 329 with complete imaging information for analysis, UM were discovered in 60 (18%): 52 (18%) of 293 proximal PDAC and 8 (22%) of 36 distal PDAC. In proximal PDAC, there was a linear relationship in the frequency of UM as a function of the weekly IOI (R(2) = .99; P = .006). For distal PDAC, no significant difference in the frequency of UM as a function of IOI was observed.
CONCLUSION: For proximally located PDAC, the frequency of UM increases with greater imaging-to-operation interval. Performing imaging at a high volume, pancreatic surgery center compared with elsewhere was not associated with a decrease in the rate of UM. Obtaining timely diagnostic imaging for proximal PDAC may improve the accuracy of preoperative staging, and thereby reduce the number of operations not producing oncologic benefit.
Copyright © 2011. Published by Mosby, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22000171     DOI: 10.1016/j.surg.2011.07.048

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  20 in total

1.  Unnecessary preoperative biliary drainage: impact on perioperative outcomes of resectable periampullary tumors.

Authors:  Jean-Baptiste Cazauran; Julie Perinel; Vahan Kepenekian; Michel El Bechwaty; Gennaro Nappo; Mathieu Pioche; Thierry Ponchon; Mustapha Adham
Journal:  Langenbecks Arch Surg       Date:  2017-10-31       Impact factor: 3.445

2.  Preparing for prospective clinical trials: a national initiative of an excellence registry for consecutive pancreatic cancer resections.

Authors:  Odo Gangl; Klaus Sahora; Peter Kornprat; Christian Margreiter; Florian Primavesi; Evelyne Bareck; Martin Schindl; Friedrich Längle; Dietmar Öfner; Hans-Jörg Mischinger; Johann Pratschke; Michael Gnant; Reinhold Függer
Journal:  World J Surg       Date:  2014-02       Impact factor: 3.352

Review 3.  Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival.

Authors:  Marianne Sinn; Marcus Bahra; Timm Denecke; Sue Travis; Uwe Pelzer; Hanno Riess
Journal:  World J Gastrointest Oncol       Date:  2016-03-15

4.  Neoadjuvant therapy for pancreatic cancer: an ongoing debate.

Authors:  Suzanne Russo; M Wasif Saif
Journal:  Therap Adv Gastroenterol       Date:  2016-05-10       Impact factor: 4.409

5.  Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy?

Authors:  Chad A Barnes; Ashley N Krepline; Mohammed Aldakkak; Callisia N Clarke; Kathleen K Christians; Abdul H Khan; Bryan C Hunt; Paul S Ritch; Ben George; William A Hall; Beth A Erickson; Douglas B Evans; Susan Tsai
Journal:  J Gastrointest Surg       Date:  2017-08-28       Impact factor: 3.452

6.  Neoadjuvant treatment is always justified for small PDAC, especially for clinical T1? - Debate from the position of Pros.

Authors:  Jin-Seok Heo
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-06-30

Review 7.  Neoadjuvant therapy for pancreas cancer: past lessons and future therapies.

Authors:  Jeffrey M Sutton; Daniel E Abbott
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

8.  Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox.

Authors:  Stephan Kruger; Karoline Schirle; Michael Haas; Alexander Crispin; Jörg Schirra; Julia Mayerle; Jan G D'Haese; Wolfgang G Kunz; Jens Ricke; Steffen Ormanns; Thomas Kirchner; Sebastian Kobold; Matthias Ilmer; Leonie Gebauer; Christoph B Westphalen; Michael von Bergwelt-Baildon; Jens Werner; Volker Heinemann; Stefan Boeck
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-23       Impact factor: 4.553

9.  Treatment of borderline resectable pancreatic cancer.

Authors:  Amanda B Cooper; Ching-Wei D Tzeng; Matthew H G Katz
Journal:  Curr Treat Options Oncol       Date:  2013-09

10.  Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer.

Authors:  Siva P Raman; Sushanth Reddy; Matthew J Weiss; Lindsey L Manos; John L Cameron; Lei Zheng; Joseph M Herman; Ralph H Hruban; Elliot K Fishman; Christopher L Wolfgang
Journal:  AJR Am J Roentgenol       Date:  2015-01       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.